Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Price Performance

Cellectis stock opened at $3.10 on Friday. The company’s 50-day moving average price is $2.63 and its two-hundred day moving average price is $2.73. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.58. The stock has a market cap of $172.30 million, a P/E ratio of -1.80 and a beta of 3.08. Cellectis has a twelve month low of $0.96 and a twelve month high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. The firm had revenue of $1.99 million for the quarter. Cellectis had a negative return on equity of 99.88% and a negative net margin of 1,087.66%. As a group, analysts expect that Cellectis will post -1.06 EPS for the current year.

Institutional Investors Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. boosted its holdings in Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned 0.76% of Cellectis worth $1,125,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.